If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?
Strong genetic evidence supports an imbalance between production and clearance of amyloid β-protein (Aβ) in people with Alzheimer disease (AD). Microglia that are potentially involved in alternative mechanisms are actually integral to the amyloid cascade. Fluid biomarkers and brain imaging place acc...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-07-01
|
| Series: | PLoS Biology |
| Online Access: | https://doi.org/10.1371/journal.pbio.3001694 |
| _version_ | 1798037149117841408 |
|---|---|
| author | Christian Haass Dennis Selkoe |
| author_facet | Christian Haass Dennis Selkoe |
| author_sort | Christian Haass |
| collection | DOAJ |
| description | Strong genetic evidence supports an imbalance between production and clearance of amyloid β-protein (Aβ) in people with Alzheimer disease (AD). Microglia that are potentially involved in alternative mechanisms are actually integral to the amyloid cascade. Fluid biomarkers and brain imaging place accumulation of Aβ at the beginning of molecular and clinical changes in the disease. So why have clinical trials of anti-amyloid therapies not provided clear-cut benefits to patients with AD? Can anti-amyloid therapies robustly decrease Aβ in the human brain, and if so, could this lowering be too little, too late? These central questions in research on AD are being urgently addressed. |
| first_indexed | 2024-04-11T21:22:39Z |
| format | Article |
| id | doaj.art-ec3e169332c247a8ad74d6534d81664c |
| institution | Directory Open Access Journal |
| issn | 1544-9173 1545-7885 |
| language | English |
| last_indexed | 2024-04-11T21:22:39Z |
| publishDate | 2022-07-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Biology |
| spelling | doaj.art-ec3e169332c247a8ad74d6534d81664c2022-12-22T04:02:34ZengPublic Library of Science (PLoS)PLoS Biology1544-91731545-78852022-07-01207e300169410.1371/journal.pbio.3001694If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?Christian HaassDennis SelkoeStrong genetic evidence supports an imbalance between production and clearance of amyloid β-protein (Aβ) in people with Alzheimer disease (AD). Microglia that are potentially involved in alternative mechanisms are actually integral to the amyloid cascade. Fluid biomarkers and brain imaging place accumulation of Aβ at the beginning of molecular and clinical changes in the disease. So why have clinical trials of anti-amyloid therapies not provided clear-cut benefits to patients with AD? Can anti-amyloid therapies robustly decrease Aβ in the human brain, and if so, could this lowering be too little, too late? These central questions in research on AD are being urgently addressed.https://doi.org/10.1371/journal.pbio.3001694 |
| spellingShingle | Christian Haass Dennis Selkoe If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline? PLoS Biology |
| title | If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline? |
| title_full | If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline? |
| title_fullStr | If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline? |
| title_full_unstemmed | If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline? |
| title_short | If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline? |
| title_sort | if amyloid drives alzheimer disease why have anti amyloid therapies not yet slowed cognitive decline |
| url | https://doi.org/10.1371/journal.pbio.3001694 |
| work_keys_str_mv | AT christianhaass ifamyloiddrivesalzheimerdiseasewhyhaveantiamyloidtherapiesnotyetslowedcognitivedecline AT dennisselkoe ifamyloiddrivesalzheimerdiseasewhyhaveantiamyloidtherapiesnotyetslowedcognitivedecline |